MedAdvisor (MDR.AX) Stock Price
MedAdvisor Price
Over the last 14 years MedAdvisor grew revenue by 77.8% annually, reaching 63.00 M AUD. For MedAdvisor, the net margin of -95.6% is down versus -34.6% a few years ago.
MedAdvisor stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of MedAdvisor over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how MedAdvisor stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing MedAdvisor's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | MedAdvisor Price |
|---|---|
| 12/24/2025 | 0.02 AUD |
| 12/23/2025 | 0.02 AUD |
| 12/22/2025 | 0.02 AUD |
| 12/19/2025 | 0.02 AUD |
| 12/18/2025 | 0.02 AUD |
| 12/17/2025 | 0.02 AUD |
| 12/16/2025 | 0.02 AUD |
| 12/15/2025 | 0.02 AUD |
| 12/12/2025 | 0.02 AUD |
| 12/11/2025 | 0.02 AUD |
| 12/10/2025 | 0.02 AUD |
| 12/9/2025 | 0.02 AUD |
| 12/8/2025 | 0.02 AUD |
| 12/5/2025 | 0.02 AUD |
| 12/4/2025 | 0.02 AUD |
| 12/3/2025 | 0.02 AUD |
| 12/2/2025 | 0.02 AUD |
| 12/1/2025 | 0.02 AUD |
| 11/28/2025 | 0.02 AUD |
| 11/27/2025 | 0.02 AUD |
| 11/26/2025 | 0.02 AUD |
| 11/25/2025 | 0.02 AUD |
| 11/24/2025 | 0.02 AUD |
| 11/21/2025 | 0.02 AUD |
| 11/20/2025 | 0.02 AUD |
| 11/19/2025 | 0.02 AUD |
| 11/18/2025 | 0.02 AUD |
| 11/17/2025 | 0.02 AUD |
| 11/14/2025 | 0.03 AUD |
| 11/13/2025 | 0.02 AUD |
MedAdvisor Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
MedAdvisor Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM AUD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM AUD |
| EBITM AUD |
| EBIT MARGIN% |
| NET INCOMEM AUD |
| NET INCOME GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | 1.00 | 1.00 | 4.00 | 7.00 | 9.00 | 11.00 | 40.00 | 67.00 | 97.00 | 98.00 | 62.00 | 110.00 | 112.00 | 116.00 |
| – | – | – | – | 300.00 | 75.00 | 28.57 | 22.22 | 263.64 | 67.50 | 44.78 | 1.03 | -36.73 | 77.42 | 1.82 | 3.57 |
| – | – | 3,200.00 | 100.00 | 100.00 | 85.71 | 88.89 | 81.82 | 55.00 | 50.75 | 60.82 | 54.08 | 51.61 | 51.61 | 51.61 | 51.61 |
| 32.00 | 32.00 | 32.00 | 1.00 | 4.00 | 6.00 | 8.00 | 9.00 | 22.00 | 34.00 | 59.00 | 53.00 | 32.00 | 56.77 | 57.81 | 59.87 |
| -3.00 | -2.00 | -1.00 | -2.00 | -3.00 | -4.00 | -8.00 | -9.00 | -16.00 | -16.00 | -8.00 | – | -13.00 | -21.00 | -21.00 | 3.00 |
| – | – | -100.00 | -200.00 | -75.00 | -57.14 | -88.89 | -81.82 | -40.00 | -23.88 | -8.25 | – | -20.97 | -19.09 | -18.75 | 2.59 |
| -3.00 | -11.00 | – | -3.00 | -3.00 | -4.00 | -8.00 | -9.00 | -13.00 | -17.00 | -11.00 | – | -60.00 | – | 1.00 | – |
| – | 266.67 | – | – | – | 33.33 | 100.00 | 12.50 | 44.44 | 30.77 | -35.29 | – | – | – | – | – |
| 54.76 | 73.40 | 120.51 | 81.14 | 124.86 | 25.35 | 194.31 | 231.93 | 316.51 | 378.12 | 544.96 | 548.12 | 565.56 | 565.56 | 565.56 | 565.56 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales MedAdvisor generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue MedAdvisor retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare MedAdvisor's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares MedAdvisor has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against MedAdvisor's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
MedAdvisor stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
MedAdvisor Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
MedAdvisor business model & stock analysis
MedAdvisor SWOT Analysis
Strengths
Medadvisor Ltd has a strong market presence in the healthcare industry, particularly in medication management.
The company has developed a user-friendly and innovative platform that enables patients to have better control over their medications.
Medadvisor's technology has the capability to integrate with existing systems, providing seamless integration for healthcare providers.
Weaknesses
Medadvisor relies heavily on partnerships with pharmaceutical companies and healthcare providers, creating a vulnerability to changes in these relationships.
The company has a relatively small market share and faces strong competition from established players in the industry.
Medadvisor's platform requires patients to actively engage and adopt the technology, which may pose a challenge in convincing a wider audience to use the service.
Opportunities
There is a growing demand for digital healthcare solutions, especially in the medication management space, presenting opportunities for Medadvisor to expand its user base.
The COVID-19 pandemic has accelerated the adoption of telehealth and remote patient monitoring, which aligns with Medadvisor's capabilities and opens up new market segments.
Expansion into international markets, where medication management solutions are not as well-developed, can help Medadvisor tap into new revenue streams.
Threats
Competitors may develop similar or superior medication management platforms, eroding Medadvisor's market share.
Changes in healthcare regulations and reimbursement policies could impact the adoption and utilization of Medadvisor's services.
Data privacy and security concerns may discourage potential users from adopting Medadvisor's platform, especially in light of increasing cyber threats.
MedAdvisor Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
MedAdvisor historical P/E ratio, EBIT multiple, and P/S ratio
MedAdvisor annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
MedAdvisor shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
MedAdvisor stock splits
MedAdvisor shareholder structure
| % | Name |
|---|---|
16.78062% | |
15.88393% | |
9.54560% | |
9.26331% | |
4.46020% | |
0.10628% |
MedAdvisor Beneficial Ownership Filings (SEC 13D/G)
Frequently asked questions about MedAdvisor
The business model of Medadvisor Ltd revolves around providing digital health solutions and medication management services. Medadvisor operates a cloud-based platform that aims to empower patients, pharmacies, and healthcare providers with tools to enhance medication adherence and improve health outcomes. Through its mobile app and web-based portal, Medadvisor offers features such as medication reminders, prescription management, health record access, and medication ordering. The company generates revenue through subscription fees paid by pharmacies and healthcare providers, as well as transactional fees from medication orders. Medadvisor aims to transform the healthcare industry by leveraging technology to streamline medication management and enhance patient engagement.
Medadvisor Ltd primarily operates in the healthcare industry. As a leading digital medication management company, Medadvisor provides innovative solutions to improve medication adherence and patient engagement. With its advanced platform, Medadvisor integrates with various pharmacies, healthcare providers, and pharmaceutical companies to simplify medication management for individuals. By leveraging technology, Medadvisor aims to enhance patient outcomes, streamline workflows, and promote efficient healthcare delivery. With its strong presence in the healthcare sector, Medadvisor is committed to revolutionizing the way medication is managed and improving the overall patient experience.
The main competitors of Medadvisor Ltd in the market are various companies that provide similar services in the healthcare technology sector. Some notable competitors include Fred IT, Mediserve, and DoseMe. These companies also offer innovative solutions and platforms to enhance patient medication management and improve overall healthcare outcomes. Medadvisor Ltd faces stiff competition in the market, but its strong track record, extensive customer base, and continuous product development strategies position it as a leading player in the healthcare technology industry.
MedAdvisor Ltd is a leading digital medication management company based in Australia. Established in 2010, MedAdvisor has rapidly grown to become a trusted platform for individuals and healthcare providers to manage medications. The company's innovative applications offer features such as prescription management, medication reminders, and real-time adherence monitoring. MedAdvisor also collaborates with pharmacies and pharmaceutical manufacturers to enhance medication adherence and health outcomes. With a focus on patient-centric solutions, MedAdvisor aims to streamline medication management and empower individuals in making informed decisions about their healthcare. MedAdvisor Ltd continues to expand its reach and influence in the healthcare industry, delivering essential digital solutions for improved medication adherence.
Medadvisor Ltd has achieved several significant milestones. The company successfully listed on the Australian Securities Exchange (ASX) in 2015, marking a major achievement in its corporate journey. In 2016, Medadvisor launched an innovative medication adherence platform, which has revolutionized the way patients manage their prescriptions and health. The company has rapidly expanded its user base, reaching over 3 million users in 2021. Medadvisor has also formed strategic partnerships with leading pharmacy groups and healthcare providers, enhancing its market presence and credibility. Additionally, Medadvisor has consistently demonstrated strong revenue growth and continuous technological advancements, solidifying its position as a prominent player in the healthcare technology sector.
Medadvisor Ltd is primarily present in Australia.
Medadvisor Ltd represents the values of innovation, efficiency, and patient-centered care. Their corporate philosophy is centered around leveraging technology to improve medication adherence and patient outcomes. With a focus on providing convenient and accessible healthcare solutions, Medadvisor aims to empower individuals to take control of their health and medication management. Through their user-friendly platform and comprehensive medication management system, Medadvisor strives to simplify and enhance the patient experience. By integrating various healthcare partners, Medadvisor promotes collaboration and seamless communication among healthcare professionals, patients, and pharmacies. Through their commitment to advancing healthcare solutions, Medadvisor Ltd is dedicated to improving overall patient well-being.
8 analysts currently rate the MedAdvisor stock: 0 recommend buying, 4 holding and 4 selling. For 2026, analysts expect MedAdvisor to generate revenue of 110.67 M AUD and earnings per share of 0.00 AUD.
Converted at the current exchange rate, the MedAdvisor share trades at 0.01 EUR (0.02 AUD).
Medadvisor Ltd is an Australian company specializing in digital medication management and patient support in adhering to medication plans. Their business model includes a patient app, a software solution for medical professionals, and a drug database. The Medadvisor app allows patients to manage their medications easily and sends reminders for dosages and times. It also informs users of potential medication interactions and health risks. The company provides medical professionals with a tool to monitor patient compliance with medication prescriptions. The drug database offers detailed information on medications, including ingredients, uses, dosages, and applications. Medadvisor works closely with hospitals, pharmacies, and drug manufacturers to enhance patient and professional networking. Overall, Medadvisor offers a practical solution for patients, professionals, and drug manufacturers using modern technology and strict data privacy standards.
The expected revenue of MedAdvisor is 110.67 M AUD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of MedAdvisor is 282,782.02 AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of MedAdvisor is currently 38.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the MedAdvisor stock.
The price-to-sales ratio (P/S) of MedAdvisor is currently 0.10. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the MedAdvisor stock.
The Eulerpool Quality Score for MedAdvisor is 3/10.
The ISIN of MedAdvisor is AU000000MDR6. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of MedAdvisor is MDR.AX. The ticker symbol is used to trade MedAdvisor shares on the stock exchange.
MedAdvisor paid dividends every year for the past 0 years.
MedAdvisor is assigned to the 'Health' sector.
The dividends of MedAdvisor are distributed in AUD.
MedAdvisor stock
MedAdvisor Peer Group
MedAdvisor FIGI
All fundamentals and in-depth analysis of MedAdvisor
Our stock analysis for MedAdvisor stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MedAdvisor. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.